Advertisement


Lawrence H. Einhorn, MD, on Palliative Radiation for Advanced Cancer and Symptomatic Bone Metastases

2015 Palliative Care in Oncology Symposium

Advertisement

Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the ways in which a dedicated palliative radiation consult service can improve the quality of palliative cancer care (Abstract 110).



Related Videos

Palliative Care

Ralph J. Hauke, MD: Toward Improved Quality of Life

Ralph J. Hauke, MD, of Nebraska Cancer Specialists, discusses the application of scientific analysis and research to palliative care issues, which will allow better prognostication, implementation of measures, and improved quality of life.

Symptom Management
Palliative Care

Lawrence H. Einhorn, MD, on CINV Clinical Trial Results: The Alliance A221301 Study

Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).

Palliative Care
Symptom Management

Eduardo Bruera, MD, on Cachexia Assessment and Management State of the Art

Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).

Palliative Care

Betty Ferrell, PhD, RN, on Depression and Cancer Care

Betty Ferrell, PhD, RN, of City of Hope, discusses two papers that look at an important issue from different perspectives: depression and anxiety among family caregivers of patients with advanced cancer, and the link between oncologists’ dispositional affect and depressive symptoms in their patients with metastatic cancer (Abstracts 224, 214).

Palliative Care
Symptom Management

Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV

Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).

Advertisement

Advertisement




Advertisement